GLP-1 Research Peptides | Glucagon-Like Peptide-1 Compounds
GLP-1 (glucagon-like peptide-1) is an endogenous incretin hormone secreted from intestinal L-cells in response to food intake that regulates appetite, gastric motility, and glucose-dependent insulin secretion. Synthetic GLP-1 receptor agonists represent one of the most actively investigated compound classes in metabolic research.
At Lab of Peptides, GLP-1 compounds are supplied within a research-use-only framework for qualified investigators conducting in vitro and in vivo scientific studies. The compounds below are relevant to obesity-pathway models, appetite-regulation research, beta-cell biology, metabolic syndrome investigation, and broader endocrine signaling analysis. They are not pharmaceutical finished products and are not intended for human consumption.
GLP-1 Research Peptides Available at Lab of Peptides
- Semaglutide — GLP-1 receptor agonist with 94% structural homology to human GLP-1
- Tirzepatide — dual GIP/GLP-1 receptor agonist and first-in-class incretin co-agonist research compound
- Retatrutide — triple GIP/GLP-1/glucagon receptor agonist positioned as an emerging metabolic research tool
Why GLP-1 Peptides Are Central to Metabolic Research
GLP-1 biology sits at the intersection of endocrinology, neurophysiology, and energy homeostasis. Research demonstrates that endogenous GLP-1 signaling influences satiety, gastric emptying, postprandial glucose handling, pancreatic beta-cell activity, and central appetite circuits. That makes GLP-1 receptor agonists unusually versatile tools for metabolic investigation. Studies indicate they can be used to explore how gut-derived peptide hormones communicate with the pancreas, liver, adipose tissue, and brain in integrated metabolic systems.
Semaglutide, tirzepatide, and retatrutide are often grouped together because all three sit within the incretin research category, yet they are not interchangeable. Semaglutide offers a cleaner single-target GLP-1 frame. Tirzepatide expands the question to dual GIP/GLP-1 signaling. Retatrutide extends the model further by incorporating glucagon receptor activity. For researchers, that progression provides a useful ladder of mechanistic complexity. One can investigate isolated GLP-1 agonism, then compare it against dual-agonist and triple-agonist signaling in matched preclinical designs.
GLP-1 receptor agonist research also matters because appetite regulation and glycaemic control involve both peripheral and central pathways. Investigators studying obesity models, hepatic steatosis, inflammatory metabolism, cardiovascular risk markers, or beta-cell function frequently use GLP-1 class compounds to examine how receptor activation changes energy intake, endocrine feedback loops, and tissue-level biomarkers. These compounds are therefore central not only to weight-management research, but to a broader map of metabolic disease mechanisms.
GLP-1 Receptor Agonist Research Comparison
| Compound | Receptor targets | MW | Research focus |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | 4113.58 Da | Single-pathway incretin signaling, appetite regulation, gastric emptying, glucose-dependent insulin research |
| Tirzepatide | GIP and GLP-1 receptor agonist | 4813.45 Da | Dual incretin co-agonism, metabolic control, endocrine interaction, obesity-pathway comparison |
| Retatrutide | GIP, GLP-1, and glucagon receptor agonist | 4731.33 Da | Triple-agonist metabolic signaling, energy expenditure models, emerging obesity and liver-metabolism research |
Research Applications
- Appetite regulation and gut-brain signaling research
- Beta-cell function and glucose-dependent insulin secretion studies
- Cardiovascular risk marker and inflammatory-metabolism investigation
- NASH and NAFLD preclinical models
- Glycaemic control pathway comparison across single, dual, and triple agonists
Frequently Asked Questions
What is a GLP-1 research peptide?
A GLP-1 research peptide is a compound used to investigate glucagon-like peptide-1 receptor biology and related incretin mechanisms. These compounds are studied in vitro and in vivo to examine appetite signaling, insulin dynamics, gastric motility, and metabolic regulation. Lab of Peptides supplies them for research use only.
How does semaglutide differ from tirzepatide in research?
Semaglutide is generally investigated as a single GLP-1 receptor agonist. Tirzepatide is studied as a dual GIP/GLP-1 receptor agonist. This means tirzepatide introduces a second incretin pathway, which can change how researchers frame energy balance, endocrine cross-talk, and metabolic endpoint design.
What is retatrutide and why is it significant in metabolic research?
Retatrutide is an emerging triple-agonist compound targeting GIP, GLP-1, and glucagon receptors. Studies indicate it is significant because it broadens the incretin framework into a more complex metabolic signaling model, making it useful for comparative obesity, energy expenditure, and liver-metabolism research.
Are GLP-1 peptides the same as Ozempic or Wegovy?
Lab of Peptides supplies research-grade GLP-1 receptor agonist compounds for in vitro and in vivo scientific investigation only. These are not pharmaceutical products and are not for human consumption or therapeutic use.
For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.